Moderna MRNA kicked off 2025 with mixed first-quarter results. While its streamlining efforts improved bottom-line numbers, ...

A little over a month after announcing her departure from Moderna, Kate Cronin has begun her “next adventure.” Cronin has ...

Moderna stock was falling on Thursday after the company reported a first-quarter loss and a slide in revenue and laid out ...

Moderna (MRNA) was in focus Thursday morning after the vaccine maker announced plans to expand its cost efficiency and ...

The pandemic accelerated Moderna's evolution into a commercial-stage biotech, and we expect that the firm's ramp-up in manufacturing and clinical know-how will pave the way for faster timelines ...

Moderna faces revenue declines, regulatory setbacks, and market challenges as COVID-19 vaccine demand wanes. Learn more about ...

With license in hand and the plant now fully operational, Moderna is free to use the site for commercial production of mRNA shots, which will then be beholden to MHRA's standard review process ...

Moderna Q1 EPS loss of $(2.52 ... period last year and the continued normalization of COVID-19 into a seasonal commercial market, with demand expected to be concentrated in the second half ...

MRNA reports mixed Q1 results. The company reiterates 2025 sales guidance but announces a cost-cutting initiative to reduce ...

Overall, Moderna ranks at the bottom across all metrics when compared to its peers. Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018.

Moderna's RSV vaccine for adults aged 60 years ... last year and the continued normalization of COVID into a seasonal commercial market, with demand expected to be concentrated in the second ...

While the pressure of declining revenues is concerning, Moderna’s encouraging commercial launch plans and a robust pipeline of mRNA-based therapies indicate that the company is actively ...